Is The Autoimmune Brain Panel™ Right For Your Patient?
Only test of its kind
Providing hope for patients with treatment-resistant conditions.
Approximately 800 million individuals worldwide 1 suffer from neurologic, psychiatric and behavioral disorders. Typically, the standard of care is treatment with psychotropic drugs. However, 20-60% of these patients do not respond to treatment 2 and fail to improve because, in some cases, the root cause is immune-mediated and goes undiagnosed.
That’s all changing with the Autoimmune Brain Panel™ – the only commercially available test of its kind that assists clinicians in diagnosing and treating immune-mediated neuropsychiatric disorders. More than 3,200 clinicians globally are utilizing the Panel to improve the lives of chronically ill patients – giving hope to those most difficult to treat.
Focus Areas
The Autoimmune Brain Panel™ can assist clinicians in identifying an underlying autoimmune process in patients with various treatment-resistant neurologic and/or psychiatric symptoms.
Testing with the Panel may be helpful if you have a patient suffering from any of the following disorders, who has not responded to treatment.
Why Test?
Evidence of autoimmune process
Presence of infection
Determines course of treatment
Improves chances of recovery
Reliable test results
Decades of research
References
- Hannah Ritchie and Max Roser (2018) – “Mental Health”. Published online at OurWorldInData.org.
- Howes, O. D., et al. (2022). “Treatment resistance in psychiatry: state of the art and new directions.” Mol Psychiatry 27(1): 58-72.
- Shin Y-W, Lee S-T, Park K-I, et al. Treatment strategies for autoimmune encephalitis. Therapeutic Advances in Neurological Disorders. January 2018. doi:10.1177/1756285617722347. https://journals.sagepub.com/doi/pdf/10.1177/1756285617722347
- Brenton JN, Goodkin HP. Antibody-Mediated Autoimmune Encephalitis in Childhood. Pediatr Neurol. 2016 Jul;60:13-23. doi: 10.1016/j.pediatrneurol.2016.04.004. Epub 2016 Apr 12. PMID: 27343023. https://www.pedneur.com/article/S0887-8994(15)30139-9/pdf
- Shimasaki C, Frye RE, Trifiletti R, Cooperstock M, Kaplan G, Melamed I, Greenberg R, Katz A, Fier E, Kem D, Traver D, Dempsey T, Latimer ME, Cross A, Dunn JP, Bentley R, Alvarez K, Reim S, Appleman J. Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms. J Neuroimmunol. 2020 Feb 15;339:577138. doi: 10.1016/j.jneuroim.2019.577138. Epub 2019 Dec 15. PMID: 31884258.